about
Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancerObesity and colorectal cancer: role of adipokines in tumor initiation and progressionEstimated glomerular filtration rate is an easy predictor of venous thromboembolism in cancer patients undergoing platinum-based chemotherapyRehabilitation in neuro-oncology: a meta-analysis of published data and a mono-institutional experience.Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapyPharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.Type 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant StressOverexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis.Effects of conventional therapeutic interventions on the number and function of regulatory T cells.Platinum-based compounds and risk for cardiovascular toxicity in the elderly: role of the antioxidants in chemoprevention.Insulinemia and the risk of breast cancer and its relapse.Obesity-driven inflammation and colorectal cancer.Monoclonal antibodies in gastrointestinal cancers.Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.Clinical models and biochemical predictors of VTE in lung cancer.Immune reaction and colorectal cancer: friends or foes?Impact of VEGF gene polymorphisms in elderly cancer patients: clinical outcome and toxicity.Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases.Ensuring Sample Quality for Biomarker Discovery Studies - Use of ICT Tools to Trace Biosample Life-cycle.Predictive value of HDL cholesterol for cancer-associated venous thromboembolism during chemotherapy.Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio.Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies.RFID as a new ICT tool to monitor specimen life cycle and quality control in a biobank.Impact of endoscopic ultrasound-guided fine-needle aspiration and multidisciplinary approach in the management of abdominal or mediastinal mass.Impact of chemotherapy on venous thromboembolism: comment to: regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study.Cardiac sarcomas: an update.Targeted therapy in first line treatment of RAS wild type colorectal cancer.Are there alternative ways to quantify the real benefit of novel agents in oncology? - the 'death pace'.Determinants of homocysteine levels in colorectal and breast cancer patients.von Hippel Lindau disease with colon adenocarcinoma, renal cell carcinoma and adrenal pheochromocytoma.Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B).A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice.TNF-α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy.Caregiver distress in the early phases of cancer.SPRECware: software tools for Standard PREanalytical Code (SPREC) labeling - effective exchange and search of stored biospecimens.Pleiotropic effects of PPARγ agonist on hemostatic activation in type 2 diabetes mellitus.Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients.Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer.VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients.
P50
Q24324198-5251DB44-BC78-40A2-87F8-9DBC4443FA45Q26853740-C09552CD-1BD0-4D69-80DA-0EA7FC41E649Q33577831-17BC330E-CB3A-4C21-BD5D-F5405E77626FQ33783229-F2A259B1-3B66-45C2-B7DE-60CE1DD0BEB6Q34272566-56D79421-C3D5-4395-86C6-B0A964412D32Q35039274-C28D25B9-4350-46C3-9B29-01B03CEC703BQ35782187-A5F96C5B-C636-4E17-84AC-5A8AF3C02630Q36057732-0B07B2BD-207D-4A8C-9CDA-0F68BCDE57DEQ37390970-D4541884-B2A8-4203-A2B9-DFB81F7C7CDCQ37877245-9F2F9F7B-062C-4484-BF26-73CDAD05F30BQ38005770-3BAA75A0-56B2-4514-9D82-04FC80B7063FQ38049173-A6EE0C2C-43E1-4B03-ADAA-20905A075076Q38084684-AEB7A860-6E05-427B-82CA-EFBFBD676133Q38184622-017F3063-E078-46CE-95FD-1F2ACDD34DAEQ38205701-2E2BD32A-BADA-4CBF-A94A-0123F68021CFQ38254123-11DA6743-BF9A-48E3-8663-C446E69C26EEQ38307997-AAB40BA8-C321-41D4-A866-BF8960734CCFQ38413737-F13ECBFD-B2D5-48E9-9C36-685D320DFBF5Q38564821-C1602ECE-3FE3-457E-9DBA-F077DEF19F7BQ38626800-6C569A66-B219-47CA-9F2F-1EB32FE52936Q39123264-2F9451E8-A86D-4D85-AB88-683CC57BFDC4Q39157050-8C11C4DF-807D-4A03-93FE-1B95B488B480Q39626187-84FD4443-5F57-4BBE-909E-B39F5CA7023AQ39749956-556B97DD-FDBB-4C95-BAE8-C782BBD29456Q40901752-4FDC1FBD-BDFC-4B34-99E9-E356C2C811B0Q42704249-ED1FC164-26DF-4CEB-A021-C955ED6463D3Q42961785-63F4529F-DE44-466B-9C94-5105F401EA43Q43183749-CD911D24-B360-4E6D-9715-E60A2780AFFBQ43199549-9FCC367B-6DFA-4EA0-895F-E6D6433D8553Q43257168-D9F0FB15-B277-4385-BC33-C838D209C30BQ44442546-5F44003F-CD50-42E6-9D0C-E288AFA2627BQ44512725-8C0B746C-2F0D-4A29-9DDE-26D7747922B3Q45179487-378D35BE-80CD-447F-9807-D41C557002ACQ48009833-B8E0008D-06F7-44D6-B3D2-8B36B04B9CB6Q48328942-6C998415-53CD-49C2-83DD-63236EA1193DQ50906917-E6D7CC48-1394-4034-A3D0-29FDEBFF496EQ51014063-13926D4A-8E98-44E8-85EF-36B5DEEAB964Q51367421-A162270F-03DA-42EB-931A-5BE404434182Q51369060-7FF541AC-346C-4DC2-B42F-309BB8FDDC0EQ53362939-F282D6F1-F4A1-435A-9AA3-7571F22DFDDE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mario Roselli
@ast
Mario Roselli
@en
Mario Roselli
@es
Mario Roselli
@nl
Mario Roselli
@sl
type
label
Mario Roselli
@ast
Mario Roselli
@en
Mario Roselli
@es
Mario Roselli
@nl
Mario Roselli
@sl
prefLabel
Mario Roselli
@ast
Mario Roselli
@en
Mario Roselli
@es
Mario Roselli
@nl
Mario Roselli
@sl
P106
P21
P31
P496
0000-0002-2431-6689